The cohort skews toward English-language US-shipping research-grade vendors
Van Haren R, Mehran R, Correa A, Antonoff M, Hofstetter W, Roth J, Sepesi B, Swisher SG , Vaporciyan AA, Walsh G, Rice D
(PubMed) Jeon YH, Park YH, Lee JH, Hong JH, Kim IY
These conventional strategies often come with drawbacks such as side effects, recurrence, or restricted use, underscoring the need for complementary, non-pharmacological alternatives [1]

Findings: WEIGHT LOSS IN ADOLESCENTS The STEP TEENS study detailed below evaluated the effects of Wegovy on weight loss in obese adolescents aged 12 - 17 years RCT STEP TEENS Study - Wegovy vs Placebo for Weight Loss in Obese Adolescents, NEJM (2022) [PubMed abstract] The STEP TEENS study enrolled 201 obese adolescents aged 12 - 17 years Main inclusion criteria Age 12 to 10% Baseline characteristics Average age 15.4 years Female sex - 62% Average weight - 238 lbs (108 kg) Average BMI - 37 Randomized treatment groups Group 1 (134 patients): Wegovy 2.4 mg once weekly Group 2 (67 patients): Placebo Before treatment, all patients underwent a 12-week run-in phase where they received lifestyle interventions Wegovy was started at 0.25 mg once weekly and titrated to 2.4 mg over 16 weeks Percentage change in BMI from baseline to week 68 Primary outcome: Results Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone Findings: Summary Wegovy caused impressive weight loss in the STEP TEENS study, and its effects were greater than other drugs approved for adolescent obesity (see Qsymia and Saxenda)

When anchor meals are built around these three components, they give your body more of what it needs to maintain a healthy metabolism, protect lean mass, and continue making progress